Please login to the form below

Not currently logged in
Email:
Password:

Research Pipeline

This page shows the latest Research Pipeline news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: GSK unveils R&D plan, Keytruda OK'd for lymphoma by NICE

Daily Brief: GSK unveils R&D plan, Keytruda OK'd for lymphoma by NICE

News from pharma, biotech and healthcare. 23andMe alliance part of GSK’s new research plan. ... GSK’s CEO Emma Walmsley (pictured) has restated her determination to revive the firm’s research pipeline in a statement this morning, ahead of an

Latest news

  • GSK: we won’t be splitting up any time soon

    The company has 27 immunomodulatory new molecular entities (NME) in clinical trials, around 60% of its total clinical pipeline. ... GSK is investing $300m in the firm, and says a long-term partnership to exploit its genetic databases will help it advance

  • Daily brief: Novartis spends big on ezcema, Daily brief: Novartis spends big on ezcema,

    Novartis already has ZPL389 in its pipeline, a phase II ezcema treatment it gained with the acquisition of Ziarco two years ago. ... The company, based in London and New York, has four ongoing clinical programmes, one compassionate use programme and a

  • BenevolentAI claims AI first with new Cambridge facility BenevolentAI claims AI first with new Cambridge facility

    BenevolentAI claims AI first with new Cambridge facility. Says its new drug discovery and development base will cover the entire research process. ... The company has previously generated novel drug candidates to treat a range of complex and previously

  • Artificial intelligence firm licenses Janssen candidates for development Artificial intelligence firm licenses Janssen candidates for development

    Janssen has licensed a number of pipeline candidates to a UK artificial intelligence company that wants to use technology to innovate the drug development process. ... The London-based firm said the agreement would enable it to accelerate its development

  • Top three therapeutic areas lead pharma’s pipeline Top three therapeutic areas lead pharma’s pipeline

    Top three therapeutic areas lead pharma’ s pipeline. Oncology dominates followed by CNS disorders and infectious diseases. ... Oncology, central nervous system (CNS) disorders and infectious diseases account for 68% of the overall pharmaceutical

More from news
Approximately 3 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    There are also a number of other drugs coming through the research pipelines. ... Pipeline growing. While Entresto and ivabradine promise to make a significant impact in HF, there are also a number of other investigational drugs coming through the

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    Research pipeline. Research at Eisai is focused on three key areas: neuroscience, oncology and vascular/immunological diseases. ... Commercial expansion. But it's not just in research spending that Eisai is bucking industry trends.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics